

In re: Rizzieri et al.
Serial No.: 10/008,062
Filed: October 19, 2001
Page 2

Listing of Claims

The following list of claims will replace all prior versions and listings of claims in the application.

1. (Previously Presented) A method of treating lymphoma in a subject in need thereof, comprising:

administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a treatment effective amount, wherein said antibody is coupled to a radioisotope.

2. (Original) A method according to claim 1, wherein said antibody is a monoclonal antibody.

3. (Original) A method according to claim 1, wherein said subject is a human subject.

4. (Original) A method according to claim 1, wherein said antibody is selected from the group consisting of monoclonal antibody 81C6 and antibodies that bind to the epitope bound by monoclonal antibody 81C6.

5. (Original) A method according to claim 1, wherein said lymphoma is Hodgkin's lymphoma.

6. (Original) A method according to claim 1, wherein said lymphoma is Non-Hodgkin's lymphoma.

7. (Canceled)

8. (Previously Presented) A method according to claim 1, wherein said radioisotope is selected from the group consisting of ^{131}I , ^{90}Y , ^{211}At , ^{212}Bi , ^{67}Cu , ^{186}Re , ^{188}Re , and ^{212}Pb .

In re: Rizzieri et al.
Serial No.: 10/008,062
Filed: October 19, 2001
Page 3

9. (Previously Presented) A method according to claim 1, wherein said radioisotope is ^{131}I .

10. (Previously Presented) A method according to claim 1, wherein said antibody coupled to a radioisotope is administered in an amount of from 10 mCi to 100 mCi.

11. (Original) A method according to claim 1, wherein said administering step is a parenteral injection step.

12. (Original) A method of treating Non-Hodgkin's Lymphoma in a human subject in need thereof, comprising:

parenterally administering to a human subject afflicted with lymphoma a monoclonal antibody that binds to tenascin in a treatment effective amount;

wherein said antibody is selected from the group consisting of monoclonal antibody 81C6 and antibodies that bind to the epitope bound by monoclonal antibody 81C6; and

wherein said antibody is coupled to a radioisotope.

13. (Original) A method according to claim 12, wherein said Non-Hodgkin's Lymphoma is unresponsive to chemotherapy treatment selected from the group consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment.

14. (Original) A method according to claim 12, wherein said Non-Hodgkin's Lymphoma is unresponsive to rituximab treatment.

15. (Original) A method according to claim 12, wherein said radioisotope is selected from the group consisting of ^{131}I , ^{90}Y , ^{211}At , ^{212}Bi , ^{67}Cu , ^{186}Re , ^{188}Re , and ^{212}Pb .

16. (Original) A method according to claim 12, wherein said radioisotope is ^{131}I .

17. (Previously Presented) A method according to claim 12, wherein said antibody coupled to a radioisotope is administered in an amount of from 10 mCi to 100 mCi.

In re: Rizzieri et al.
Serial No.: 10/008,062
Filed: October 19, 2001
Page 4

18. (Original) A method according to claim 12, wherein said Non-Hodgkin's lymphoma is a low grade lymphoma.

19. (Original) A method according to claim 12, wherein said Non-Hodgkin's lymphoma is an intermediate grade lymphoma.

20. (Original) A method according to claim 12, wherein said Non-Hodgkin's lymphoma is a high grade lymphoma.

21. (Original) A method according to claim 12, wherein said parenteral administration step is carried out by intravenous injection.

22. (Previously Presented) A method of treating Non-Hodgkin's lymphoma in a human subject in need thereof, comprising:

parenterally administering to a human subject afflicted with Non-Hodgkin's lymphoma 81C6 monoclonal antibody coupled to ¹³¹I in an amount of from 10 mCi to 100 mCi, wherein the Non-Hodgkin's lymphoma is unresponsive to chemotherapy.

23. (New) A method of treating lymphoma in a human subject in need thereof, comprising:

administering intravenously to a subject afflicted with lymphoma an antibody that binds to tenascin in a treatment effective amount, wherein said antibody is coupled to a radioisotope and retention of said antibody in the lymphoma is at least two-fold greater compared to normal tissue.

24. (New) A method according to claim 12, wherein said antibody is a murine monoclonal antibody 81C6.